Olivas Arroyo C
Unidad de Radiofarmacia, Servicio de Medicina Nuclear, Hospital Universitari i Politècnic La Fe, Valencia, España.
Radiologia. 2016 Nov-Dec;58(6):468-480. doi: 10.1016/j.rx.2016.07.003. Epub 2016 Aug 31.
Positron emission tomography (PET) is an imaging technique that has grown greatly in recent years. PET is considered a fundamental tool in oncology, and it also has indications in other fields such as neurology and cardiology. Although F-fluorodeoxyglucose (F-FDG) is the radiopharmaceutical most widely used in PET, the availability of new radiotracers has been a key element in the expansion of the use of PET. These new radiopharmaceuticals have made it possible to study different biological targets that are essential for obtaining greater knowledge and better characterization of different diseases and have thus contributed to the research and development of different therapeutic agents. This article provides a description of different PET radiopharmaceutical, structured according to their areas of application. Some of these radiotracers are already commercially available, whereas others are still under research or pending approval by regulatory bodies.
正电子发射断层扫描（PET）是一种近年来发展迅速的成像技术。PET被认为是肿瘤学中的一项基础工具，在神经学和心脏病学等其他领域也有应用。尽管氟脱氧葡萄糖（F-FDG）是PET中使用最广泛的放射性药物，但新型放射性示踪剂的出现是PET应用扩展的关键因素。这些新型放射性药物使得研究不同的生物靶点成为可能，而这些靶点对于深入了解和更好地表征不同疾病至关重要，从而推动了不同治疗药物的研发。本文根据不同PET放射性药物的应用领域对其进行了描述。其中一些放射性示踪剂已可商业化获取，而其他一些仍在研究中或有待监管机构批准。
